SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.86
+1.17%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 402.86x
- P/S forward
- 77.46x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 20.33x
- Price / sales
- —
- Price / cash flow
- -98.48x
Enterprise value
- Enterprise value
- $2.7B
- EV / sales
- —
- EV / EBITDA
- -104.86x
- EV / EBIT
- -75.56x
- Market cap
- $2.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026